SERA - צמיחת הכנסות ב-12 חודשים נגררים Sera Prognostics

Sera Prognostics operates within the US legal framework on a humanitarian basis, which excludes geopolitical risks. The leadership team is integrating predictive diagnostics into medicine through partnerships with insurers. Diversification of proteomic test distribution minimizes market threats, as confirmed by this chart of LTM sales volume changes compared to last year. The value of 1.00 expresses the current metric value, capturing the company's development vector.

Sera Prognostics leverages outsourcing for clinical trials and test production to maintain a focus on innovation, a trend reflected in the rolling 12-month sales volume chart compared to the same period last year. This indicator measures the real pace of revenue expansion adjusted for seasonality, allowing investors to determine whether actual sales are outpacing inflation and confirming a sustainable growth in the business's fundamental trend.